X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufacturing technologies.
Lead Product(s): EDIT-202
Therapeutic Area: Oncology Product Name: EDIT-202
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Editas Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 19, 2023
Details:
Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies.
Lead Product(s): iPSC-NK Cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
The collaboration will leverage Shoreline’s deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s extensive cell therapy expertise to develop novel allogeneic candidates for a range of hematologic malignancies.
Lead Product(s): Allogeneic Cell Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Partnership June 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
